CN114008023B - 索吡溴铵的晶型及其制备方法 - Google Patents

索吡溴铵的晶型及其制备方法 Download PDF

Info

Publication number
CN114008023B
CN114008023B CN202080034880.8A CN202080034880A CN114008023B CN 114008023 B CN114008023 B CN 114008023B CN 202080034880 A CN202080034880 A CN 202080034880A CN 114008023 B CN114008023 B CN 114008023B
Authority
CN
China
Prior art keywords
compound
crystalline form
crystalline
content
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080034880.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114008023A (zh
Inventor
丸林千能
渡边将仁
H·R·布林克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bricker Biotechnology
Kaken Pharmaceutical Co Ltd
Original Assignee
Bricker Biotechnology
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bricker Biotechnology, Kaken Pharmaceutical Co Ltd filed Critical Bricker Biotechnology
Publication of CN114008023A publication Critical patent/CN114008023A/zh
Application granted granted Critical
Publication of CN114008023B publication Critical patent/CN114008023B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080034880.8A 2019-05-23 2020-05-22 索吡溴铵的晶型及其制备方法 Active CN114008023B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851880P 2019-05-23 2019-05-23
US62/851880 2019-05-23
PCT/JP2020/020210 WO2020235665A1 (en) 2019-05-23 2020-05-22 Crystalline form of sofpironium bromide and preparation method thereof

Publications (2)

Publication Number Publication Date
CN114008023A CN114008023A (zh) 2022-02-01
CN114008023B true CN114008023B (zh) 2024-02-09

Family

ID=72146250

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080034880.8A Active CN114008023B (zh) 2019-05-23 2020-05-22 索吡溴铵的晶型及其制备方法

Country Status (18)

Country Link
US (3) US20220298108A1 (https=)
EP (1) EP3972955A4 (https=)
JP (2) JP6748329B1 (https=)
KR (1) KR20220011671A (https=)
CN (1) CN114008023B (https=)
AU (1) AU2020277881B2 (https=)
BR (1) BR112021023241A2 (https=)
CA (1) CA3139948A1 (https=)
CL (1) CL2021003047A1 (https=)
CO (1) CO2021017456A2 (https=)
IL (1) IL288285B1 (https=)
MX (1) MX2021014163A (https=)
MY (1) MY206154A (https=)
PH (1) PH12021552915A1 (https=)
SG (1) SG11202111678WA (https=)
TW (2) TWI838531B (https=)
WO (1) WO2020235665A1 (https=)
ZA (1) ZA202109514B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220298108A1 (en) * 2019-05-23 2022-09-22 Kaken Pharmaceutical Co., Ltd. Crystalline form of sofpironium bromide and preparation method thereof
EP4213158A1 (en) 2020-11-13 2023-07-19 Ahead Biocomputing, Co. Ltd Information processing device, information processing method, recording medium recording information processing program, and information processing system
CN115925603B (zh) * 2022-11-29 2025-07-22 山东齐都药业有限公司 索吡溴铵的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058971A2 (en) * 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic esters
WO2007059021A1 (en) * 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic zwitterions
WO2018026869A1 (en) * 2016-08-02 2018-02-08 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
MX357741B (es) * 2012-07-06 2018-07-23 Laboratorios Senosiain S A De C V Star Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
US9512166B2 (en) * 2012-09-05 2016-12-06 Amri Ssci, Llc Cocrystals of progesterone
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10282282B2 (en) * 2016-06-29 2019-05-07 Synopsys, Inc. Automated HTTP user flows simulator
US20220298108A1 (en) * 2019-05-23 2022-09-22 Kaken Pharmaceutical Co., Ltd. Crystalline form of sofpironium bromide and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058971A2 (en) * 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic esters
WO2007059021A1 (en) * 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic zwitterions
WO2018026869A1 (en) * 2016-08-02 2018-02-08 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Preparation and biological effects of pure stereoisomeric novel soft anticholinergics;Tóth-Sarudy, É. 等;《Pharmazie》;第61卷(第2期);第90-96页 *
Synthes is and pharmacologic al effects of new, N -substituted soft antich olinergics based on glycopyrrolate;F. Ji等;《Journal of Pharmacy and Pharmacology》;第57卷(第11期);第1429页右栏第3段-第1430页左栏第1段2R-SGE、第1431页图1 *

Also Published As

Publication number Publication date
JP2020189856A (ja) 2020-11-26
IL288285B1 (en) 2026-02-01
TW202110796A (zh) 2021-03-16
CA3139948A1 (en) 2020-11-26
SG11202111678WA (en) 2021-11-29
US20210395197A1 (en) 2021-12-23
JP2020189839A (ja) 2020-11-26
AU2020277881A1 (en) 2021-12-09
CN114008023A (zh) 2022-02-01
ZA202109514B (en) 2023-12-20
US11566000B2 (en) 2023-01-31
CL2021003047A1 (es) 2022-09-20
AU2020277881B2 (en) 2025-03-06
CO2021017456A2 (es) 2022-01-17
US11584715B2 (en) 2023-02-21
EP3972955A4 (en) 2023-07-05
TW202411205A (zh) 2024-03-16
KR20220011671A (ko) 2022-01-28
IL288285A (en) 2022-01-01
BR112021023241A2 (pt) 2022-01-04
TWI870116B (zh) 2025-01-11
MX2021014163A (es) 2022-01-04
JP6748329B1 (ja) 2020-08-26
TWI838531B (zh) 2024-04-11
EP3972955A1 (en) 2022-03-30
JP7605598B2 (ja) 2024-12-24
US20220298108A1 (en) 2022-09-22
PH12021552915A1 (en) 2022-04-04
MY206154A (en) 2024-12-02
WO2020235665A1 (en) 2020-11-26
US20210171460A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
EP3029039B1 (en) Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
CN108947891B (zh) 利用三光气安全制备匹莫范色林及其酒石酸盐的方法
CN114008023B (zh) 索吡溴铵的晶型及其制备方法
HK1225719A1 (en) Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl) benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
CN102596897A (zh) 一种n-(苯基甲基)丙酰胺衍生物的多种固体形态及制备方法
WO2016131431A1 (en) Solid forms of empagliflozin
KR101408370B1 (ko) 아리피프라졸-유기산 공결정을 함유하는 제제 및 이의 제조 방법
HK40068368A (en) Crystalline form of sofpironium bromide and preparation method thereof
WO2018119291A1 (en) Synthetic methods
HK40068368B (zh) 索吡溴铵的晶型及其制备方法
CN105859611A (zh) 一种阿扎那韦硫酸氢盐a型结晶的制备方法
JP2022539342A (ja) ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法
HK1183034B (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
HK40080449A (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068368

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant